Michael Halpin - Vericel Corp Chief Officer
| VCEL Stock | USD 46.26 0.92 1.95% |
Executive
Mr. Michael Halpin is appointed as Chief Operating Officer of the Company, effective June 15, 2019. Mr. Halpin joined the Company on April 10, 2017 as Senior Vice President, Quality and Regulatory Affairs, where he was responsible for quality activities and regulatory strategy. From 2016 until joining the Company, Mr. Halpin served as Vice President, North American region regulatory head at Sanofi Genzyme. Prior to that, Mr. Halpin served as Vice President, Regulatory Affairs for Genzymes biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Epicel and MACI. Prior to Genzyme, Mr. Halpin held a number of regulatory, quality and clinical affairs positions at several medical device companies, including AbbottMediSense, C.R. Bard and Abiomed since 2019.
| Age | 64 |
| Tenure | 6 years |
| Address | 64 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 588 5555 |
| Web | https://www.vcel.com |
Michael Halpin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Halpin against Vericel Corp stock is an integral part of due diligence when investing in Vericel Corp. Michael Halpin insider activity provides valuable insight into whether Vericel Corp is net buyers or sellers over its current business cycle. Note, Vericel Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vericel Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Halpin over six months ago Acquisition by Michael Halpin of 2063 shares of Vericel Corp at 2.65 subject to Rule 16b-3 | ||
Michael Halpin over a year ago Disposition of 7874 shares by Michael Halpin of Vericel Corp at 44.71 subject to Rule 16b-3 |
Vericel Corp Management Efficiency
Return On Tangible Assets is expected to rise to 0.03 this year. Return On Capital Employed is expected to rise to 0.01 this year. At this time, Vericel Corp's Intangible Assets are quite stable compared to the past year. Return On Tangible Assets is expected to rise to 0.03 this year, although the value of Non Currrent Assets Other will most likely fall to about 528.2 K. Vericel Corp's management efficiency ratios could be used to measure how well Vericel Corp manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
| Michael CPA | Blueprint Medicines Corp | 53 | |
| JD II | Regenxbio | 54 | |
| Christina MBA | Blueprint Medicines Corp | 49 | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Julian Baker | Blueprint Medicines Corp | 58 | |
| Olivier Danos | Regenxbio | 67 | |
| Jason Hoitt | Stoke Therapeutics | 47 | |
| Matt Yang | Cytokinetics | N/A | |
| Stephen MD | Regenxbio | 56 | |
| Lily Cheung | Pliant Therapeutics | 52 | |
| Erin Graves | Revolution Medicines | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Douglas Snyder | Ideaya Biosciences | 61 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Diane Weiser | Cytokinetics | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.04 | ||||
| Return On Asset | 0.0072 |
Vericel Corp Ord Leadership Team
Elected by the shareholders, the Vericel Corp's board of directors comprises two types of representatives: Vericel Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vericel. The board's role is to monitor Vericel Corp's management team and ensure that shareholders' interests are well served. Vericel Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vericel Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan Siegal, VP Officer | ||
| Mike Gilligan, Senior Sales | ||
| Michael Halpin, Chief Officer | ||
| Patrick Fowler, Senior Strategy | ||
| Sean Flynn, Chief Officer | ||
| Joseph Mara, CFO Treasurer | ||
| MB FRCSEd, Chief Officer | ||
| Eric Burns, Vice Relations | ||
| Patrick Helfrich, Vice Strategy | ||
| Roland DeAngelis, Senior Operations | ||
| Heidi Hassen, Senior Resources | ||
| Dominick Esq, President CEO |
Vericel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vericel Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.04 | ||||
| Return On Asset | 0.0072 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 2.35 B | ||||
| Shares Outstanding | 49.97 M | ||||
| Shares Owned By Insiders | 1.02 % | ||||
| Shares Owned By Institutions | 98.98 % | ||||
| Number Of Shares Shorted | 3.61 M | ||||
| Price To Earning | 357.33 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Vericel Corp Ord. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vericel Corp. If investors know Vericel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vericel Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.476 | Earnings Share 0.2 | Revenue Per Share | Quarterly Revenue Growth 0.16 | Return On Assets |
The market value of Vericel Corp Ord is measured differently than its book value, which is the value of Vericel that is recorded on the company's balance sheet. Investors also form their own opinion of Vericel Corp's value that differs from its market value or its book value, called intrinsic value, which is Vericel Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vericel Corp's market value can be influenced by many factors that don't directly affect Vericel Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vericel Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vericel Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vericel Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.